ZNRF3
E3 ubiquitin-protein ligase ZNRF3
Protein Summary
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signaling pathway by mediating the ubiquitination and subsequent degradation of Wnt receptor complex components Frizzled and LRP6. Acts on both canonical and non-canonical Wnt signaling pathway. Acts as a tumor suppressor in the intestinal stem cell zone by inhibiting the Wnt signaling pathway, thereby resticting the size of the intestinal stem cell zone (PubMed:22575959). Along with RSPO2 and RNF43, constitutes a master switch that governs limb specification (By similarity).
- ENST00000402174
- ENSP00000384456
- ENSG00000183579
- ENST00000406323
- ENSP00000384553
- ENST00000544604
- ENSP00000443824
- KIAA1133
- RNF203
- RNF203
- BK747E2.3
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
cell type or tissue | 0.76 | ||
histone modification site profile | 0.74 | ||
transcription factor | 0.71 | ||
tissue sample | 0.63 | ||
cell line | 0.62 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 46.21 (req: < 5)
Gene RIFs: 30 (req: <= 3)
Antibodies: 80 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 46.21 (req: >= 5)
Gene RIFs: 30 (req: > 3)
Antibodies: 80 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 13
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0